Navigation Links
Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
Date:5/4/2009

inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF) in the eye. Based on this mechanism of action, POT-4 holds the potential to be effective against both dry and wet AMD.

About AMD

AMD is the leading cause of blindness in the elderly of the western world and affects more than 10 million patients in the United States alone. The current standard of care for AMD relies primarily on angiogenesis inhibitors, an approach geared towards the approximately 10-15% of AMD patients with complications resulting from ocular angiogenesis (growth of new blood vessels and bleeding in the back of the eye). No drug currently on the market has been approved for the treatment of the remaining patients, who suffer from the so-called "dry" form of the disease.

About the Complement System and POT-4

Complement activation is an inflammatory process involving dozens of plasma proteins, ultimately leading to cell membrane disruption through the membrane attack complex (MAC). Activation of the complement system is an important part of the body's defensive immune response against pathogens such as bacteria and viruses. In spite of its defensive function, inappropriate or excessive complement activation can have destructive consequences. Over the past three years, multiple scientific publications have strongly linked variants of genes encoding components of the complement system with a predisposition toward AMD.

POT-4 binds tightly to complement component C3, preventing its participation in the complement activation cascade. As C3 is the central component of all major complement activation pathways, its inhibition effectively shuts down downstream complement activation that could otherwise lead to local inflammation, tissue damage and upregulation of angio
'/>"/>

SOURCE Potentia Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
2. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
3. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
4. Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
5. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
6. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
7. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
8. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
9. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
10. Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
11. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... N.J. , March 26, 2015 IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... of ANDA submissions now pending at the FDA to ... CEO of the Company, commented, "On March 2, 2015, ...
(Date:3/26/2015)...  CNBC profiled MJ Freeway , a business software ... "How I Did It," which features companies with unique paths ... released yesterday, illustrates how two tech entrepreneurs from ... the marijuana industry. ... Poinsett and Jessica Billingsley used their experience in ...
(Date:3/26/2015)... 26, 2015 Editor Note: ... bottom . Investor-Edge has initiated coverage on ... Salix Pharmaceuticals Ltd (NASDAQ: SLXP ), Hospira Inc. ... ), and Akorn Inc. (NASDAQ: AKRX ). Free ... http://get.Investor-Edge.com/pdf/?c=Mylan&d=26-Mar-2015&s=MYL . The US markets declined on Wednesday, March ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 3Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 4Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 5
... LITTLE FALLS, N.J., Feb. 2, 2011 Projects ... provider of continuing medical education (CME/CE) activities, previously ... game-changing Living Medical eTextbook. Now the iPhone app ... recognized by iMedicalApps ( www.imedicalapps.com ) as one ...
... and PRINCETON, N.J., Feb. 2, 2011 Eli Lilly ... Squibb Company (NYSE: BMY ) announced today ... two global Phase III studies evaluating necitumumab, an investigational ... cell lung cancer (NSCLC). (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO) ...
Cached Medicine Technology:Living Medical eTextbook iPhone App from Projects In Knowledge® Named to Top 20 List of Free Medical Apps 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 3Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 4Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 5Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 6Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 7Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 8Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 9Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 10
(Date:3/27/2015)... San Diego, CA (PRWEB) March 27, 2015 ... will launch its Protect Our Children (POC) NOW! vitamin ... at the Medical University of South Carolina (MUSC), and ... POC will be available at no cost to a ... less gestation who live within these two service areas. ...
(Date:3/27/2015)... 27, 2015 When struck with the ... to know where to begin. The latest eBook ... accident attorney, offers accident victims a clear and concise ... to ensure their personal injury claim is seen through ... the first actions that should be taken immediately following ...
(Date:3/27/2015)... Trail mix is the perfect, healthy snack for families on ... the game! It’s portable, lightweight and provides a wide range ... new line of specialty trail mixes that satisfy your hunger ... with nutritious, 100% all natural ingredients. , These tasty combinations ... and fiber to your diet and boost energy. The mixes ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Approximately ... for Healthy Kids Coalition Lobby Day to lobby ... Health Improvement Program (SHIP). Everlast Climbing was ... PE Bill SF343/HF498 which would strengthen physical education ... student assessments and other measures to strengthen physical ...
(Date:3/27/2015)... Since September 2014, the country singer has been traveling ... been in retirement for a period of 13 years. Many ... to touring, and concert events have been booking quickly in ... out for the two shows recently scheduled for May 8 ... inventory of discounted Garth Brooks tickets for sale. , The ...
Breaking Medicine News(10 mins):Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Garth Brooks Tickets for Omaha: BuyCheapTicketsToEvents.com Draws Customers by Discounting Prices on 2015 Tickets for Garth Brooks’ Tour Stops at CenturyLink Center 2
... Weinberg is the first recipient of the science prize inaugurated ... Eva Klein. The prize is awarded in person by Crown ... 2008. The prizewinner, who is to be a leading international ... Institutet in Stockholm for two weeks to give lectures and ...
... You Be Ready with that Confident ... ... Freshening Teeth Cleaners, an effective way to,clean teeth and freshen breath on-the-go. ... of,teeth, leaving them feeling smooth and clean., A great smile is ...
... /PRNewswire/ - There is new hope for vertigo,and ... DizzyFIX,patients with vertigo can now treat themselves. Studies ... visual device helps treat the most common,type of ... DizzyFIX has received a number of medical research ...
... Sequences of DNA in the human genome that originated ... our bodies and are even essential for a healthy ... of Microbiology Today. , Retrovirus infections represent the most ... its genome into the DNA of the host cell, ...
... REDWOOD CITY, Calif., Jan. 29 Maxygen, Inc.,(Nasdaq: ... of,improved protein drugs, will host a conference call to ... results at 11:30 a.m.,ET (8:30 a.m. PT) on Tuesday, ... host the call. A press release announcing,Maxygen,s fourth quarter ...
... Gross Proceeds Expected to Be Approximately $168.6 Million, ... or the "Company") announced today that it has agreed ... Investment Bank, as sole,underwriter, in an underwritten public offering. ... option to purchase up to an additional,585,000 shares of ...
Cached Medicine News:Health News:Kimberly-Clark Launches DentaBurst(TM) Freshening Teeth Cleaners 2Health News:All Star Sales Introduces DizzyFIX a New Treatment for Vertigo and Dizziness 2Health News:Maxygen to Host Fourth Quarter and Year End 2007 Financial Results Conference Call on February 12, 2008 2Health News:Ventas Enters Agreement to Sell Common Stock 2Health News:Ventas Enters Agreement to Sell Common Stock 3Health News:Ventas Enters Agreement to Sell Common Stock 4Health News:Ventas Enters Agreement to Sell Common Stock 5
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
... Featuring new technology, such as a ... shaft and lens housings, this arthroscope has ... accomplished by EO, Steris and steam autoclaving ... diameters. Light post/adapters to fit ACMI, Wolf, ...
... The Passport II delivery device is the ... for C11UB. Its simple-to-use syringe technology allows ... a small incision. The blue colored plunger ... to protect the haptics during insertion. The ...
Medicine Products: